APO Research
Talk to an analyst

APO RESEARCH · REPORT

Infection Prevention Surveillance

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Infection Prevention Surveillance Market Outlook and Growth Opportunities 2026

28 December 2025193 pages

Choose your research edition.

Industry ResearchInfection Prevention Surveillance Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Infection Prevention Surveillance Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Infection Prevention Surveillance Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032192 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Infection Prevention Surveillance Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Infection Prevention Surveillance Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

The global Infection Prevention Surveillance market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Infection Prevention Surveillance is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Infection Prevention Surveillance is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Infection Prevention Surveillance is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Infection Prevention Surveillance market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Infection Prevention Surveillance market include BD, Wolters Kluwer, Gojo Industries Inc., International Business Machines Corporation, Premier Inc., Alpha Source Inc., RLDatixS. C., Baxter International Inc. and BioVigil, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Infection Prevention Surveillance market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Infection Prevention Surveillance and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Infection Prevention Surveillance revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Infection Prevention Surveillance market.

Infection Prevention Surveillance Segment by Company

BD

Wolters Kluwer

Gojo Industries Inc.

International Business Machines Corporation

Premier Inc.

Alpha Source Inc.

RLDatixS. C.

Baxter International Inc.

BioVigil

Johnson & Son

Infection Prevention Surveillance Segment by Type

Bloodstream Infections

Surgical Site Infections

Gastrointestinal Infections

Urinary Tract Infections (UTI)

Others

Infection Prevention Surveillance Segment by Application

Hospitals & Clinics

Ambulatory Surgical Centers

Academic Institutes

Others

Infection Prevention Surveillance Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Infection Prevention Surveillance status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Infection Prevention Surveillance key companies, revenue, market share, and recent developments.

3. To split the Infection Prevention Surveillance breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Infection Prevention Surveillance market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Infection Prevention Surveillance significant trends, drivers, influence factors in global and regions.

6. To analyze Infection Prevention Surveillance competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Infection Prevention Surveillance market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Infection Prevention Surveillance and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Infection Prevention Surveillance.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Infection Prevention Surveillance industry.

Chapter 3: Detailed analysis of Infection Prevention Surveillance company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Infection Prevention Surveillance in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Infection Prevention Surveillance in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Infection Prevention Surveillance Industry Trends Table 2. Infection Prevention Surveillance Industry Drivers Table 3. Infection Prevention Surveillance Industry Opportunities and Challenges Table 4. Infection Prevention Surveillance Industry Restraints Table 5. Global Infection Prevention Surveillance Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Infection Prevention Surveillance Revenue Share by Company (2021-2026) Table 7. Global Infection Prevention Surveillance Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Infection Prevention Surveillance Key Company Manufacturing Base & Headquarters Table 9. Global Infection Prevention Surveillance Company, Product Type & Application Table 10. Global Infection Prevention Surveillance Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Infection Prevention Surveillance by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Bloodstream Infections Table 15. Significant Companies of Surgical Site Infections Table 16. Significant Companies of Gastrointestinal Infections Table 17. Significant Companies of Urinary Tract Infections (UTI) Table 18. Significant Companies of Others Table 19. Global Infection Prevention Surveillance Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 20. Global Infection Prevention Surveillance Sales Value by Type (2021-2026) & (US$ Million) Table 21. Global Infection Prevention Surveillance Sales Value by Type (2027-2032) & (US$ Million) Table 22. Global Infection Prevention Surveillance Sales Value Share by Type (2021-2026) Table 23. Global Infection Prevention Surveillance Sales Value Share by Type (2027-2032) Table 24. Significant Companies of Hospitals & Clinics Table 25. Significant Companies of Ambulatory Surgical Centers Table 26. Significant Companies of Academic Institutes Table 27. Significant Companies of Others Table 28. Global Infection Prevention Surveillance Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Infection Prevention Surveillance Sales Value by Application (2021-2026) & (US$ Million) Table 30. Global Infection Prevention Surveillance Sales Value by Application (2027-2032) & (US$ Million) Table 31. Global Infection Prevention Surveillance Sales Value Share by Application (2021-2026) Table 32. Global Infection Prevention Surveillance Sales Value Share by Application (2027-2032) Table 33. Global Infection Prevention Surveillance Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Infection Prevention Surveillance Sales Value by Region (2021-2026) & (US$ Million) Table 35. Global Infection Prevention Surveillance Sales Value Share by Region (2021-2026) Table 36. Global Infection Prevention Surveillance Sales Value by Region (2027-2032) & (US$ Million) Table 37. Global Infection Prevention Surveillance Sales Value Share by Region (2027-2032) Table 38. Global Infection Prevention Surveillance Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Infection Prevention Surveillance Sales Value by Country (2021-2026) & (US$ Million) Table 40. Global Infection Prevention Surveillance Sales Value Market Share by Country (2021-2026) Table 41. Global Infection Prevention Surveillance Sales Value by Country (2027-2032) & (US$ Million) Table 42. Global Infection Prevention Surveillance Sales Value Market Share by Country (2027-2032) Table 43. BD Company Information Table 44. BD Business Overview Table 45. BD Infection Prevention Surveillance Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. BD Infection Prevention Surveillance Product Portfolio Table 47. BD Recent Development Table 48. Wolters Kluwer Company Information Table 49. Wolters Kluwer Business Overview Table 50. Wolters Kluwer Infection Prevention Surveillance Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. Wolters Kluwer Infection Prevention Surveillance Product Portfolio Table 52. Wolters Kluwer Recent Development Table 53. Gojo Industries Inc. Company Information Table 54. Gojo Industries Inc. Business Overview Table 55. Gojo Industries Inc. Infection Prevention Surveillance Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. Gojo Industries Inc. Infection Prevention Surveillance Product Portfolio Table 57. Gojo Industries Inc. Recent Development Table 58. International Business Machines Corporation Company Information Table 59. International Business Machines Corporation Business Overview Table 60. International Business Machines Corporation Infection Prevention Surveillance Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. International Business Machines Corporation Infection Prevention Surveillance Product Portfolio Table 62. International Business Machines Corporation Recent Development Table 63. Premier Inc. Company Information Table 64. Premier Inc. Business Overview Table 65. Premier Inc. Infection Prevention Surveillance Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Premier Inc. Infection Prevention Surveillance Product Portfolio Table 67. Premier Inc. Recent Development Table 68. Alpha Source Inc. Company Information Table 69. Alpha Source Inc. Business Overview Table 70. Alpha Source Inc. Infection Prevention Surveillance Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Alpha Source Inc. Infection Prevention Surveillance Product Portfolio Table 72. Alpha Source Inc. Recent Development Table 73. RLDatixS. C. Company Information Table 74. RLDatixS. C. Business Overview Table 75. RLDatixS. C. Infection Prevention Surveillance Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. RLDatixS. C. Infection Prevention Surveillance Product Portfolio Table 77. RLDatixS. C. Recent Development Table 78. Baxter International Inc. Company Information Table 79. Baxter International Inc. Business Overview Table 80. Baxter International Inc. Infection Prevention Surveillance Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Baxter International Inc. Infection Prevention Surveillance Product Portfolio Table 82. Baxter International Inc. Recent Development Table 83. BioVigil Company Information Table 84. BioVigil Business Overview Table 85. BioVigil Infection Prevention Surveillance Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. BioVigil Infection Prevention Surveillance Product Portfolio Table 87. BioVigil Recent Development Table 88. Johnson & Son Company Information Table 89. Johnson & Son Business Overview Table 90. Johnson & Son Infection Prevention Surveillance Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Johnson & Son Infection Prevention Surveillance Product Portfolio Table 92. Johnson & Son Recent Development Table 93. Research Programs/Design for This Report Table 94. Authors List of This Report Table 95. Secondary Sources Table 96. Primary Sources List of Figures Figure 1. Infection Prevention Surveillance Product Image Figure 2. Global Infection Prevention Surveillance Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Infection Prevention Surveillance Market Size (2021-2032) & (US$ Million) Figure 4. Global Infection Prevention Surveillance Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Bloodstream Infections Image Figure 8. Surgical Site Infections Image Figure 9. Gastrointestinal Infections Image Figure 10. Urinary Tract Infections (UTI) Image Figure 11. Others Image Figure 12. Global Infection Prevention Surveillance Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 13. Global Infection Prevention Surveillance Sales Value Share 2021 VS 2025 VS 2032 Figure 14. Global Infection Prevention Surveillance Sales Value Share by Type (2021-2032) Figure 15. Hospitals & Clinics Image Figure 16. Ambulatory Surgical Centers Image Figure 17. Academic Institutes Image Figure 18. Others Image Figure 19. Global Infection Prevention Surveillance Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Infection Prevention Surveillance Sales Value Share 2021 VS 2025 VS 2032 Figure 21. Global Infection Prevention Surveillance Sales Value Share by Application (2021-2032) Figure 22. Global Infection Prevention Surveillance Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 23. Global Infection Prevention Surveillance Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 24. North America Infection Prevention Surveillance Sales Value (2021-2032) & (US$ Million) Figure 25. North America Infection Prevention Surveillance Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Europe Infection Prevention Surveillance Sales Value (2021-2032) & (US$ Million) Figure 27. Europe Infection Prevention Surveillance Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Asia-Pacific Infection Prevention Surveillance Sales Value (2021-2032) & (US$ Million) Figure 29. Asia-Pacific Infection Prevention Surveillance Sales Value Share by Country (%), 2025 VS 2032 Figure 30. South America Infection Prevention Surveillance Sales Value (2021-2032) & (US$ Million) Figure 31. South America Infection Prevention Surveillance Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Middle East & Africa Infection Prevention Surveillance Sales Value (2021-2032) & (US$ Million) Figure 33. Middle East & Africa Infection Prevention Surveillance Sales Value Share by Country (%), 2025 VS 2032 Figure 34. USA Infection Prevention Surveillance Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. USA Infection Prevention Surveillance Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. USA Infection Prevention Surveillance Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Canada Infection Prevention Surveillance Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Canada Infection Prevention Surveillance Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Canada Infection Prevention Surveillance Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Mexico Infection Prevention Surveillance Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Mexico Infection Prevention Surveillance Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Mexico Infection Prevention Surveillance Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Germany Infection Prevention Surveillance Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Germany Infection Prevention Surveillance Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Germany Infection Prevention Surveillance Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. France Infection Prevention Surveillance Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. France Infection Prevention Surveillance Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. France Infection Prevention Surveillance Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. U.K. Infection Prevention Surveillance Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. U.K. Infection Prevention Surveillance Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. U.K. Infection Prevention Surveillance Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Italy Infection Prevention Surveillance Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Italy Infection Prevention Surveillance Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Italy Infection Prevention Surveillance Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Spain Infection Prevention Surveillance Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Spain Infection Prevention Surveillance Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Spain Infection Prevention Surveillance Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Russia Infection Prevention Surveillance Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Russia Infection Prevention Surveillance Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Russia Infection Prevention Surveillance Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Netherlands Infection Prevention Surveillance Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Netherlands Infection Prevention Surveillance Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Netherlands Infection Prevention Surveillance Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Nordic Countries Infection Prevention Surveillance Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Nordic Countries Infection Prevention Surveillance Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Nordic Countries Infection Prevention Surveillance Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. China Infection Prevention Surveillance Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. China Infection Prevention Surveillance Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. China Infection Prevention Surveillance Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Japan Infection Prevention Surveillance Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Japan Infection Prevention Surveillance Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Japan Infection Prevention Surveillance Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. South Korea Infection Prevention Surveillance Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. South Korea Infection Prevention Surveillance Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. South Korea Infection Prevention Surveillance Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. India Infection Prevention Surveillance Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. India Infection Prevention Surveillance Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. India Infection Prevention Surveillance Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Australia Infection Prevention Surveillance Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Australia Infection Prevention Surveillance Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Australia Infection Prevention Surveillance Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Southeast Asia Infection Prevention Surveillance Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Southeast Asia Infection Prevention Surveillance Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Southeast Asia Infection Prevention Surveillance Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Brazil Infection Prevention Surveillance Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Brazil Infection Prevention Surveillance Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Brazil Infection Prevention Surveillance Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Argentina Infection Prevention Surveillance Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Argentina Infection Prevention Surveillance Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Argentina Infection Prevention Surveillance Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Chile Infection Prevention Surveillance Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Chile Infection Prevention Surveillance Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Chile Infection Prevention Surveillance Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Colombia Infection Prevention Surveillance Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Colombia Infection Prevention Surveillance Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Colombia Infection Prevention Surveillance Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Peru Infection Prevention Surveillance Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Peru Infection Prevention Surveillance Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Peru Infection Prevention Surveillance Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Infection Prevention Surveillance Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Saudi Arabia Infection Prevention Surveillance Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Saudi Arabia Infection Prevention Surveillance Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Israel Infection Prevention Surveillance Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Israel Infection Prevention Surveillance Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Israel Infection Prevention Surveillance Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. UAE Infection Prevention Surveillance Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. UAE Infection Prevention Surveillance Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. UAE Infection Prevention Surveillance Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Turkey Infection Prevention Surveillance Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Turkey Infection Prevention Surveillance Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Turkey Infection Prevention Surveillance Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Iran Infection Prevention Surveillance Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Iran Infection Prevention Surveillance Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Iran Infection Prevention Surveillance Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Egypt Infection Prevention Surveillance Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Egypt Infection Prevention Surveillance Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Egypt Infection Prevention Surveillance Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Years Considered Figure 119. Research Process Figure 120. Key Executives Interviewed

Scope & coverage.

Types
  • Bloodstream Infections
  • Surgical Site Infections
  • Gastrointestinal Infections
  • Urinary Tract Infections (UTI)
  • Others
Applications
  • Hospitals & Clinics
  • Ambulatory Surgical Centers
  • Academic Institutes
  • Others
Companies covered
  • BD
  • Wolters Kluwer
  • Gojo Industries Inc.
  • International Business Machines Corporation
  • Premier Inc.
  • Alpha Source Inc.
  • RLDatixS. C.
  • Baxter International Inc.
  • BioVigil
  • Johnson & Son

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Infection Prevention Surveillance Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Infection Prevention Surveillance Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Infection Prevention Surveillance Market Dynamics
  1. 2.1 Infection Prevention Surveillance Industry Trends
  2. 2.2 Infection Prevention Surveillance Industry Drivers
  3. 2.3 Infection Prevention Surveillance Industry Opportunities and Challenges
  4. 2.4 Infection Prevention Surveillance Industry Restraints
3 Infection Prevention Surveillance Market by Company
  1. 3.1 Global Infection Prevention Surveillance Company Revenue Ranking in 2025
  2. 3.2 Global Infection Prevention Surveillance Revenue by Company (2021-2026)
  3. 3.3 Global Infection Prevention Surveillance Company Ranking (2024-2026)
  4. 3.4 Global Infection Prevention Surveillance Company Manufacturing Base and Headquarters
  5. 3.5 Global Infection Prevention Surveillance Company Product Type and Application
  6. 3.6 Global Infection Prevention Surveillance Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Infection Prevention Surveillance Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Infection Prevention Surveillance Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Infection Prevention Surveillance Market by Type
  1. 4.1 Infection Prevention Surveillance Type Introduction
  2. 4.1.1 Bloodstream Infections
  3. 4.1.2 Surgical Site Infections
  4. 4.1.3 Gastrointestinal Infections
  5. 4.1.4 Urinary Tract Infections (UTI)
  6. 4.1.5 Others
  7. 4.2 Global Infection Prevention Surveillance Sales Value by Type
  8. 4.2.1 Global Infection Prevention Surveillance Sales Value by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Infection Prevention Surveillance Sales Value by Type (2021-2032)
  10. 4.2.3 Global Infection Prevention Surveillance Sales Value Share by Type (2021-2032)
5 Infection Prevention Surveillance Market by Application
  1. 5.1 Infection Prevention Surveillance Application Introduction
  2. 5.1.1 Hospitals & Clinics
  3. 5.1.2 Ambulatory Surgical Centers
  4. 5.1.3 Academic Institutes
  5. 5.1.4 Others
  6. 5.2 Global Infection Prevention Surveillance Sales Value by Application
  7. 5.2.1 Global Infection Prevention Surveillance Sales Value by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Infection Prevention Surveillance Sales Value by Application (2021-2032)
  9. 5.2.3 Global Infection Prevention Surveillance Sales Value Share by Application (2021-2032)
6 Infection Prevention Surveillance Regional Value Analysis
  1. 6.1 Global Infection Prevention Surveillance Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Infection Prevention Surveillance Sales Value by Region (2021-2032)
  3. 6.2.1 Global Infection Prevention Surveillance Sales Value by Region: 2021-2026
  4. 6.2.2 Global Infection Prevention Surveillance Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Infection Prevention Surveillance Sales Value (2021-2032)
  7. 6.3.2 North America Infection Prevention Surveillance Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Infection Prevention Surveillance Sales Value (2021-2032)
  10. 6.4.2 Europe Infection Prevention Surveillance Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Infection Prevention Surveillance Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Infection Prevention Surveillance Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Infection Prevention Surveillance Sales Value (2021-2032)
  16. 6.6.2 South America Infection Prevention Surveillance Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Infection Prevention Surveillance Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Infection Prevention Surveillance Sales Value Share by Country, 2025 VS 2032
7 Infection Prevention Surveillance Country-level Value Analysis
  1. 7.1 Global Infection Prevention Surveillance Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Infection Prevention Surveillance Sales Value by Country (2021-2032)
  3. 7.2.1 Global Infection Prevention Surveillance Sales Value by Country (2021-2026)
  4. 7.2.2 Global Infection Prevention Surveillance Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Infection Prevention Surveillance Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Infection Prevention Surveillance Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Infection Prevention Surveillance Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Infection Prevention Surveillance Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Infection Prevention Surveillance Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Infection Prevention Surveillance Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Infection Prevention Surveillance Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Infection Prevention Surveillance Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Infection Prevention Surveillance Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Infection Prevention Surveillance Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Infection Prevention Surveillance Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Infection Prevention Surveillance Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Infection Prevention Surveillance Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Infection Prevention Surveillance Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Infection Prevention Surveillance Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Infection Prevention Surveillance Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Infection Prevention Surveillance Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Infection Prevention Surveillance Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Infection Prevention Surveillance Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Infection Prevention Surveillance Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Infection Prevention Surveillance Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Infection Prevention Surveillance Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Infection Prevention Surveillance Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Infection Prevention Surveillance Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Infection Prevention Surveillance Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Infection Prevention Surveillance Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Infection Prevention Surveillance Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Infection Prevention Surveillance Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Infection Prevention Surveillance Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Infection Prevention Surveillance Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Infection Prevention Surveillance Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Infection Prevention Surveillance Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Infection Prevention Surveillance Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Infection Prevention Surveillance Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Infection Prevention Surveillance Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Infection Prevention Surveillance Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Infection Prevention Surveillance Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Infection Prevention Surveillance Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Infection Prevention Surveillance Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Infection Prevention Surveillance Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Infection Prevention Surveillance Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Infection Prevention Surveillance Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Infection Prevention Surveillance Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Infection Prevention Surveillance Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Infection Prevention Surveillance Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Infection Prevention Surveillance Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Infection Prevention Surveillance Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Infection Prevention Surveillance Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Infection Prevention Surveillance Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Infection Prevention Surveillance Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Infection Prevention Surveillance Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Infection Prevention Surveillance Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Infection Prevention Surveillance Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Infection Prevention Surveillance Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Infection Prevention Surveillance Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Infection Prevention Surveillance Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Infection Prevention Surveillance Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Infection Prevention Surveillance Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Infection Prevention Surveillance Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Infection Prevention Surveillance Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Infection Prevention Surveillance Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Infection Prevention Surveillance Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Infection Prevention Surveillance Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Infection Prevention Surveillance Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Infection Prevention Surveillance Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Infection Prevention Surveillance Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Infection Prevention Surveillance Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Infection Prevention Surveillance Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Infection Prevention Surveillance Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Infection Prevention Surveillance Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Infection Prevention Surveillance Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Infection Prevention Surveillance Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Infection Prevention Surveillance Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Infection Prevention Surveillance Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Infection Prevention Surveillance Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Infection Prevention Surveillance Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Infection Prevention Surveillance Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Infection Prevention Surveillance Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Infection Prevention Surveillance Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Infection Prevention Surveillance Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Infection Prevention Surveillance Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Infection Prevention Surveillance Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Infection Prevention Surveillance Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Infection Prevention Surveillance Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 BD
  2. 8.1.1 BD Company Information
  3. 8.1.2 BD Business Overview
  4. 8.1.3 BD Infection Prevention Surveillance Revenue and Gross Margin (2021-2026)
  5. 8.1.4 BD Infection Prevention Surveillance Product Portfolio
  6. 8.1.5 BD Recent Developments
  7. 8.2 Wolters Kluwer
  8. 8.2.1 Wolters Kluwer Company Information
  9. 8.2.2 Wolters Kluwer Business Overview
  10. 8.2.3 Wolters Kluwer Infection Prevention Surveillance Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Wolters Kluwer Infection Prevention Surveillance Product Portfolio
  12. 8.2.5 Wolters Kluwer Recent Developments
  13. 8.3 Gojo Industries Inc.
  14. 8.3.1 Gojo Industries Inc. Company Information
  15. 8.3.2 Gojo Industries Inc. Business Overview
  16. 8.3.3 Gojo Industries Inc. Infection Prevention Surveillance Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Gojo Industries Inc. Infection Prevention Surveillance Product Portfolio
  18. 8.3.5 Gojo Industries Inc. Recent Developments
  19. 8.4 International Business Machines Corporation
  20. 8.4.1 International Business Machines Corporation Company Information
  21. 8.4.2 International Business Machines Corporation Business Overview
  22. 8.4.3 International Business Machines Corporation Infection Prevention Surveillance Revenue and Gross Margin (2021-2026)
  23. 8.4.4 International Business Machines Corporation Infection Prevention Surveillance Product Portfolio
  24. 8.4.5 International Business Machines Corporation Recent Developments
  25. 8.5 Premier Inc.
  26. 8.5.1 Premier Inc. Company Information
  27. 8.5.2 Premier Inc. Business Overview
  28. 8.5.3 Premier Inc. Infection Prevention Surveillance Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Premier Inc. Infection Prevention Surveillance Product Portfolio
  30. 8.5.5 Premier Inc. Recent Developments
  31. 8.6 Alpha Source Inc.
  32. 8.6.1 Alpha Source Inc. Company Information
  33. 8.6.2 Alpha Source Inc. Business Overview
  34. 8.6.3 Alpha Source Inc. Infection Prevention Surveillance Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Alpha Source Inc. Infection Prevention Surveillance Product Portfolio
  36. 8.6.5 Alpha Source Inc. Recent Developments
  37. 8.7 RLDatixS. C.
  38. 8.7.1 RLDatixS. C. Company Information
  39. 8.7.2 RLDatixS. C. Business Overview
  40. 8.7.3 RLDatixS. C. Infection Prevention Surveillance Revenue and Gross Margin (2021-2026)
  41. 8.7.4 RLDatixS. C. Infection Prevention Surveillance Product Portfolio
  42. 8.7.5 RLDatixS. C. Recent Developments
  43. 8.8 Baxter International Inc.
  44. 8.8.1 Baxter International Inc. Company Information
  45. 8.8.2 Baxter International Inc. Business Overview
  46. 8.8.3 Baxter International Inc. Infection Prevention Surveillance Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Baxter International Inc. Infection Prevention Surveillance Product Portfolio
  48. 8.8.5 Baxter International Inc. Recent Developments
  49. 8.9 BioVigil
  50. 8.9.1 BioVigil Company Information
  51. 8.9.2 BioVigil Business Overview
  52. 8.9.3 BioVigil Infection Prevention Surveillance Revenue and Gross Margin (2021-2026)
  53. 8.9.4 BioVigil Infection Prevention Surveillance Product Portfolio
  54. 8.9.5 BioVigil Recent Developments
  55. 8.10 Johnson & Son
  56. 8.10.1 Johnson & Son Company Information
  57. 8.10.2 Johnson & Son Business Overview
  58. 8.10.3 Johnson & Son Infection Prevention Surveillance Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Johnson & Son Infection Prevention Surveillance Product Portfolio
  60. 8.10.5 Johnson & Son Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst